ENZON PHARMACEUTICALS, INC.
Loading stock data...
Key Financial Metrics (TTM | FY 2025)
-
Revenue
$-3.41M
Net Income
-0.07
EPS (Diluted)
$-4.92M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
$-5.31M
Returns & Efficiency
Return on Assets (ROA)
-7.96%
Return on Equity (ROE)
-
Gross Profit
-
Operating Income
$-5.31M
Financial Health
Total Assets
$42.81M
Total Debt
-
Debt to Equity
-x
Current Ratio
58.57
Debt Analysis
Debt to EBITDA
-
Debt to Free Cash Flow
-
Cash & Equivalents
-
Net Debt
-
Capital Returns
Return on Invested Capital (ROIC)
-
Invested Capital
-
Stockholders Equity
-
Revenue Growth
-
Market Valuation
Market Cap
-
P/E Ratio
-
Price to Book
-
EPS (Diluted)
$-0.07
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Insider Transactions
Neutral
Open Market Buys: -
Open Market Sales: -
Option Exercise & Sale: -
Net: -
Loading...
Loading insider transactions...
My Notes & Files
Personal Notes
Attached Files
Loading...
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address |
20 COMMERCE DRIVE, SUITE 135
CRANFORD, NJ 07016 |
| Phone | 732-980-4500 |
| Incorporated | DE, US |
| EIN | 222372868 |
| Fiscal Year End | 1231 |
| Stockholders' Equity | $-2.52M |
| Cash & Equivalents | $42.57M |
Recent Filings
View All
8-A12G/A
Amended 8-A12G
Amendment to 8-A12G registration
Filed: 2026-03-11
Local
425
Prospectus Communications
Prospectus communications under Securities Act
Filed: 2026-03-11
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-03-11
Local
SC TO-I/A
SC TO-I/A Filing
SEC regulatory filing
Filed: 2026-03-11
Local
425
Prospectus Communications
Prospectus communications under Securities Act
Filed: 2026-03-09
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-03-09
Local
SC TO-I/A
SC TO-I/A Filing
SEC regulatory filing
Filed: 2026-03-09
Local
424B3
Prospectus (Rule 424b3)
Prospectus filed under Rule 424(b)(3)
Filed: 2026-03-03
Local
SC TO-I/A
SC TO-I/A Filing
SEC regulatory filing
Filed: 2026-03-03
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2026-03-02
Local
8-A12G/A
Amended 8-A12G
Amendment to 8-A12G registration
Filed: 2026-02-27
Local
425
Prospectus Communications
Prospectus communications under Securities Act
Filed: 2026-02-27
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-02-27
Local
SC TO-I/A
SC TO-I/A Filing
SEC regulatory filing
Filed: 2026-02-27
Local
SC 14F1
SC 14F1 Filing
SEC regulatory filing
Filed: 2026-02-26
Local
Financial Statistics
Valuation
Market Cap
-
P/E Ratio (TTM)
-
Price to Book
-
EV/Revenue
-
EV/EBITDA
-
Profitability
Gross Margin
-
Operating Margin
-
Net Margin
-
ROE
-
ROA
-8.0%
Leverage & Liquidity
Debt to Equity
-
Current Ratio
58.57
Total Debt
-
Total Assets
$42.81M
Stockholders' Equity
$-2.52M
Income Statement (FY 2025)
Revenue
-
Gross Profit
-
Operating Income
$-5.31M
Net Income
$-3.41M
EPS (Diluted)
$-0.07
Cash Flow (FY 2025)
Free Cash Flow
$-4.92M
Cash & Equivalents
$42.57M
Revenue Growth
-
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...